Pipeline

Ranibizumab-eqrn will offer greater treatment access and choice for patients, payors, and providers in the US.

COMET-3 is the second of 3 studies in the AR-15512 Registrational Phase 3 Program, which is slated for completion by 2023.

If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.

A comprehensive analysis of the possible directions corporate optical practices might be headed in.

Study evaluated twice-daily administration of VUITY (pilocarpine HCI ophthalmic solution) 1.25% in adults with age-related blurry near Vision

Presbyopia awareness: Causes, risk factors, symptoms, correction options and market trends.

SECO hosted its 2022 annual meeting March 9-13 at the Ernest N. Morial Convention Center with a LIVE CE virtual meeting available to online attendees.

Pipeline treatments for presbyopia, myopia, and demodex are expanding rapidly

The removal of preservatives may be beneficial for the ocular health of glaucoma patients

The FDA has approved XIPERE for the treatment of macular edema associated with uveitis

Susvimo's new therapeutic approach for wet AMD may help patients maintain their vision with as few as 2 treatments per year

The therapy is now approved for the treatment of ocular itching caused by allergic conjunctivitis

Offer patients independence and improve quality of life by incorporating low vision services

Clinicians can offer patients both prescription and OTC options

See our latest poll results

See our latest poll results

This poll is for optometrists and eyecare professionals, only. It will close on Friday, August 13, 2021.